These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Fibrinolysis in patients with chemotherapy-induced thrombocytopenia and the effect of platelet transfusion. Heubel-Moenen FCJI; Henskens YMC; Verhezen PWM; Wetzels RJH; Schouten HC; Beckers EAM J Thromb Haemost; 2019 Jul; 17(7):1073-1084. PubMed ID: 31033178 [TBL] [Abstract][Full Text] [Related]
27. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma]. Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741 [TBL] [Abstract][Full Text] [Related]
28. Fibrinolysis during cardiac surgery. Release of tissue plasminogen activator in arterial and coronary sinus blood. Valen G; Eriksson E; Risberg B; Vaage J Eur J Cardiothorac Surg; 1994; 8(6):324-30. PubMed ID: 8086178 [TBL] [Abstract][Full Text] [Related]
29. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products. Prentice CR; Hampton KK; Grant PJ; Nelson SR; Nieuwenhuizen W; Gaffney PJ Br J Haematol; 1993 Feb; 83(2):276-81. PubMed ID: 8457476 [TBL] [Abstract][Full Text] [Related]
31. The effects of green pit viper (Trimeresurus albolabris and Trimeresurus macrops) venom on the fibrinolytic system in human. Rojnuckarin P; Intragumtornchai T; Sattapiboon R; Muanpasitporn C; Pakmanee N; Khow O; Swasdikul D Toxicon; 1999 May; 37(5):743-55. PubMed ID: 10219986 [TBL] [Abstract][Full Text] [Related]
33. Fibrinolysis during liver transplantation in humans: role of tissue-type plasminogen activator. Dzik WH; Arkin CF; Jenkins RL; Stump DC Blood; 1988 Apr; 71(4):1090-5. PubMed ID: 3128347 [TBL] [Abstract][Full Text] [Related]
34. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Stibbe J; Kluft C; Brommer EJ; Gomes M; de Jong DS; Nauta J Eur J Clin Invest; 1984 Oct; 14(5):375-82. PubMed ID: 6437836 [TBL] [Abstract][Full Text] [Related]
35. Autotransfusion management during and after cardiopulmonary bypass alters fibrin degradation and transfusion requirements. Wiefferink A; Weerwind PW; van Heerde W; Teerenstra S; Noyez L; de Pauw BE; Brouwer RM J Extra Corpor Technol; 2007 Jun; 39(2):66-70. PubMed ID: 17672185 [TBL] [Abstract][Full Text] [Related]
37. Characterization of the murine plasma fibrinolytic system. Lijnen HR; van Hoef B; Beelen V; Collen D Eur J Biochem; 1994 Sep; 224(3):863-71. PubMed ID: 7523120 [TBL] [Abstract][Full Text] [Related]
38. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Chandler WL; Fitch JC; Wall MH; Verrier ED; Cochran RP; Soltow LO; Spiess D Thromb Haemost; 1995 Nov; 74(5):1293-7. PubMed ID: 8607112 [TBL] [Abstract][Full Text] [Related]
39. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol. Winkler UH; Schindler AE; Endrikat J; Düsterberg B Contraception; 1996 Feb; 53(2):75-84. PubMed ID: 8838483 [TBL] [Abstract][Full Text] [Related]
40. Epsilon-aminocaproic acid promotes the release of alpha2-antiplasmin during and after cardiopulmonary bypass. Ray MJ; Hales M; Marsh N Blood Coagul Fibrinolysis; 2001 Mar; 12(2):129-35. PubMed ID: 11302475 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]